New data presented at EANM’22 supporting methods for analysing multi-organ insulin sensitivity using PET/MRI

The 35th Annual Congress of the European Association of Nuclear Medicine (EANM) takes place on October 15-19 in Barcelona, Spain. Antaros Medical is presenting at this meeting.

Iina Laitinen (Senior Director PET Imaging at Antaros Medical) is presenting the abstract “Repeatability of pixelwise and regional analysis of glucose uptake rates measured by dynamic whole-body 18F-FDG-PET/MR in T2DM subjects” on Tuesday October 18th in the Advanced Data Analysis Top Rated Oral Presentation (TROP) session from 15:00 – 16:30.

The study involved repeated whole-body imaging of type 2 diabetes patients (T2D) patients, and was performed as a collaboration between Antaros Medical, Eli Lilly and Company, and Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, together with Clinical Trial Consultants and Uppsala University.

Type 2 diabetes is a global health problem on the rise that often brings many serious downstream complications in organs such as the heart, liver, and kidney. As such, it is necessary to consider more holistic treatment options and adopt multi-organ approaches when investigating the disease. Hallmarks of diabetes include loss of insulin sensitivity and altered glucose metabolism, and using 18F-FDG-PET imaging under hyperinsulinemic euglycemic clamp (HEC) is a potential tool for assessing these.

Combining 18F-FDG-PET imaging with MRI to create whole-body assessment provides a quantitative readout of insulin sensitivity that can then be utilised in various analysis approaches. The abstract presented at EANM describes new data on the repeatability of both the pixelwise and regional analysis endpoints in various tissues, providing support for the use of these methods for dynamic 18F-FDG-PET/MRI assessments in future multi-organ investigation in T2D.

Abstract title: Repeatability of pixelwise and regional analysis of glucose uptake rates measured by dynamic whole-body 18F-FDG-PET/MRI in T2D subjects
Abstract number: OP-686
Authors: Laitinen I, Ekström S, Haraldsson H, Korenyushkin A, Pierrou S, Litorp H, Sjöberg F, Southekal S, Lu M, Coskun T, Milicevic Z, Kullberg J, Johansson L
Advanced Data Analysis Session on Tuesday 18th @ 15:00-16:30 in the Cutting-Edge Science Track

Another abstract co-authored by Olof Eriksson, Senior Director PET Imaging at Antaros Medical and Associate Professor at Uppsala University, will be presented by Emmi Puuvuori on Wednesday October 19th.

Abstract title: PET-CT imaging of CD69 in rheumatoid arthritis model
Abstract number: OP-874
Authors: Puuvuori E, Shen Y, Zhang B, Hulsart Billström G, Persson J, Ståhlh S, Korsgren O, Löfblom J, Wermeling F, Eriksson O
Antibodies – Reliable Workhorses Session on Wednesday October 19th @ 9:45-11:15 in the “From Molecule to Man” (M2M) Track

Discover both abstracts in the EANM Abstract Book.

Share on Linkedin Share on Twitter